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Background and purpose: Glycine receptor (GlyR) α1 subunit R271Q and R271L (α1R271Q/L) 
mutations cause the neuromotor disorder, hereditary hyperekplexia. Studies suggest that the 271 
residue is located within the allosteric signaling pathway linking the agonist binding site to the 
channel gate. The present study aims to investigate a possible mechanism for restoring the 
function of the α1R271Q/L GlyR. 
Experimental approach: A 12-amino-acid segment incorporating the 271 residue on the GlyR 
α1271Q/L subunit was replaced by the homologous segment from the GlyR β subunit 
(α1Ch271Q/L GlyR). The function of the α1Ch271Q/L GlyR was examined by whole-cell patch-
clamp recording and voltage-clamp fluorometry techniques. 
Key results: The function of the α1Ch271Q/L GlyR was restored to the level of the WT α1 GlyR.  
Moreover, in the α1Ch GlyR, in contrast to the α1 GlyR, the channel function was not sensitive to 
various substitutions of the 271 residue, and the conformational change in the vicinity of the 271 
residue was uncoupled from the channel gating. 
Conclusions and implications:  The 271 residue is shifted out of the allosteric signaling pathway 
in the α1Ch GlyR. We propose that this mechanism provides a novel drug design strategy not only 
for GlyR α1R271Q/L-caused hereditary hyperekplexia, but also for any pathological condition 
that is caused by missense mutation- or covalent modification-induced disorders involving 
residues in allosteric signaling pathways. Such a strategy makes it possible to design an ideal 
drug, which only corrects the function of the mutant or modified protein without affecting the 
wild-type or naive protein. 
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Missense mutations and abnormal covalent modifications of certain residues in proteins are 
causes of a huge body of pathological conditions. Hereditary hyperekplexia (startle disease), 
which is a neuromotor disorder characterized by exaggerated startle reflexes and hypertonia in 
response to sudden unexpected auditory or tactile stimuli, is mainly caused by hereditary 
mutations to the inhibitory postsynaptic neurotransmitter receptor, the glycine receptor (GlyR) 
chloride channel (Chung et al., 2010; Harvey et al., 2008).  
 
The GlyR exists as a pentamer. Each subunit is composed of an N-terminal extracellular domain 
(ECD) and four transmembrane domains (TMD) M1-4. Agonist binding to the ECDs (Brejc et 
al., 2001; Hibbs and Gouaux, 2011; Unwin, 2005), via an allosteric signaling pathway (channel 
gating pathway), leads to the opening of the channel pore, which is lined by the M2 TMDs 
(Figure 1A) (Bocquet et al., 2009; Bouzat et al., 2004; Hibbs and Gouaux, 2011; Hilf and 
Dutzler, 2009; Hilf and Dutzler, 2008; Lee et al., 2009; Lummis et al., 2005; Unwin, 2005). 
 
The most commonly occurring hyperekplexia-causing mutations are R271Q and R271L 
(R271Q/L) in the GlyR α1 subunit (Zhou et al., 2002). This residue lies at the extracellular mouth 
of the channel pore, physically located between the agonist binding sites and channel gate (Hibbs 
and Gouaux, 2011; Hilf and Dutzler, 2009; Hilf and Dutzler, 2008; Unwin, 2005) (Figure 1A). 
The R271Q/L mutations exert their pathological effects by reducing agonist glycine sensitivity 
(Figure 2A and B) (Lynch, 2004).  Many other residue substitutions at this site, such as R271A, 
also reduce glycine sensitivity (Figure 2B) (Langosch et al., 1994; Lynch et al., 2001; Lynch et 
al., 1997; Rajendra et al., 1994). Furthermore, taurine, which is a low-efficacy GlyR agonist, 
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completely fails to activate the α1R271Q/L/A GlyR channel opening (Fig 3A and B) (Rajendra et 
al., 1995). Moreover, this residue and those in its vicinity also experience a conformational 
change during channel gating and more importantly this change is coupled to the channel gating 
process (Pless et al., 2007). Taken together, these results suggest that the 271 residue is located 
within the channel gating pathway that functionally links the agonist binding site to the channel 
gate in the GlyR (Figure 1A).  
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Hereditary hyperekplexia, including those resulting from the R271Q/L GlyR mutations, are 
currently treated by using benzodiazepines, such as clonazepam, which act presumably by 
potentiating another inhibitory postsynaptic receptor, the type A γ-aminobutyric acid receptor 
(GABAAR) (Bakker et al., 2009; Thomas et al., 2010; Zhou et al., 2002). However, the 
treatment is non-specific and symptomatic. Although there are barely any case reports, due to the 
limited literature, on the side effects of using clonazepam to treat hyperekplexia, drowsiness, 
ataxia and behavior problems have been often listed as side effects when using clonazepam to 
treat other more common neurological disorders, such as epilepsy (Browne, 1976).  Moreover, in 
contrast to the majority of hyperekplexia-causing mutations, which are recessive and do not 
require life-long treatment, the R271L/Q GlyR mutations are dominant, present life-long 
symptoms and require long-term treatment (Chung et al., 2010; Harvey et al., 2008; Rees et al., 
2006). This posits a high chance of potential serious side-effects if the benzodiazepine 
clonazepam is used. To minimize the occurrence of side effects, the ideal treatment would be one 
that specifically corrects the structural or functional defect imposed by the disease mutation. 
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Here we report that the replacement of a 12-amino-acid (12-AA) segment incorporating the 271 
residue on the GlyR α1 subunit with the homologous segment from the GlyR β subunit restores 
the function of the α1R271Q/L GlyR. Further experiments suggest that such a restoration is 
achieved by altering the local microenvironment in the vicinity of the 271 residue and in 
consequence shifting this residue out of the dominant channel gating pathway. 
 
Like residue replacement, the binding of a small molecule could also alter local conformation 
(del Sol et al., 2009; Kar et al., 2010; Kumar et al., 2000; Todd and Freire, 1999), and therefore 
our proposal could form the basis for a universal mutant or modified residue-specific drug design 
strategy: an allosteric drug (Kar et al., 2010) can be designed to alter the microenvironment in the 
vicinity of the affected residue and thereby eliminate the residue from the dominant allosteric 
signaling pathway. Such a strategy may make it possible to design an “ideal” drug that simply 
corrects the function of the mutant or modified protein without affecting the wild-type (WT) or 
naive protein. 
 
Methods 
Mutagenesis and chimera construction of the GlyR cDNAs 
 
Nomenclature used in this article conforms to the Guide to Receptors and Channels published in 
the British Journal of Pharmacology (Alexander et al., 2009). 
 
The human GlyR α1 cDNAs were subcloned into the pcDNA3.1zeo+ (Invitrogen) or pGEMHE 
(Liman et al., 1992) plasmid vectors for expression in HEK293 cells or Xenopus oocytes, 
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respectively. Site-directed mutagenesis and chimera construction were performed using the 
QuickChange (Stratagene, La Jolla, CA, USA) mutagenesis and multiple-template-based 
sequential PCR protocols, respectively. 
 
The multiple-template-based sequential PCR protocol for chimera construction was developed in 
our laboratory and has recently been described in detail elsewhere (Shan and Lynch, 2010). This 
procedure does not require the existence of restriction sites, or the purification of intermediate 
PCR products, and needs only two or three simple PCRs followed by general subcloning steps. 
Most importantly, the chimera joining sites are seamless and the success rate for construction is 
nearly 100% (Shan and Lynch, 2010). 
 
In the VCF experiments, to eliminate non-essential background cysteines, the C41A mutation 
was introduced into the GlyR α1 cDNAs in the pGEMHE vector (Shan et al., 2003), and a further 
C267S mutation was introduced into the 12-AA region of the GlyR α1Ch cDNA.  This 
manipulation did not alter channel function. 
 
HEK293 cell culture, expression and electrophysiological recording 
The effects of various substitutions of the 271 residue on the glycine and taurine sensitivity of the 
α1 and α1Ch GlyRs were determined by experiments on HEK293 cells. Details of the HEK293 cell 
culture, GlyR expression and electrophysiological recording of the HEK293 cells are described 
elsewhere (Shan et al., 2001b). Briefly, HEK293 cells were maintained in DMEM supplemented 
with 10% fetal bovine serum. Cells were transfected using a calcium phosphate precipitation 
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protocol. In addition, the pEGFP-N1 (Clontech) was co-transfected to facilitate identifying the 
transfected cells.  
 
Glycine and taurine-induced currents were measured using the whole cell patch-clamp 
configuration. Cells were treated with external Ringer’s solution and internal CsCl solution (Shan 
et al., 2001b). Cells were voltage-clamped at -40 mV.  
 
Xenopus oocyte preparation, expression and VCF recording 
VCF experiments were performed on GlyRs expressed in Xenopus oocytes. Details of oocyte 
preparation, GlyR expression and VCF recording are described elsewhere (Pless et al., 2007). 
Briefly, the mMessage mMachine kit (Ambion, Austin, TX) was used to generate capped mRNA. 
The mRNA was injected into oocytes of the female Xenopus laevis frog with 10 ng per oocyte. 
After injection, the oocytes were incubated in ND96 solution (Pless et al., 2007) for 3–4 days at 
18 °C before recording. 
 
The sulfhydryl-reactive reagents, sulforhodamine methanethiosulfonate (MTSR, Toronto 
Research Chemicals, North York, Ontario, Canada) and tetramethylrhodamine methyl ester 
(TMRM, Invitrogen), were used to label the 271C residues. On the day of recording, the oocytes 
were labeled with 10μM MTSR for 25s or 10 μM TMRM for 60 min, either in the absence or 
presence of glycine. The oocytes were then transferred to the recording chamber and perfused 
with ND96 solution. The current was recorded by the two-electrode voltage clamp configuration 
and the recording electrode was filled with 3 M KCl. Cells were voltage-clamped at -40 mV. The 
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fluorescence was recorded using the PhotoMax 200 photodiode detection system (Dagan Corp., 
Minneapolis, MN). 
 
Data analysis 
Results are expressed as mean ± standard error of the mean (SEM) of three or more independent 
experiments. The empirical Hill equation, fitted by a non-linear least squares algorithm 
(SigmaPlot 9.0, Systat Software, Point Richmond, CA), was used to calculate the EC50 values for 
glycine- or taurine-induced current and fluorescence changes. Statistical significance was 
determined using the Student’s t-test. 
 
Results 
Replacement of the 12-AA segment incorporating the 271 residue restores the function of 
α1R271Q/L GlyR 
The GlyR and the GABAAR, two major chloride-permeable postsynaptic neurotransmitter 
receptors, share common structural and functional characteristics and possibly even the same 
evolutionary origin (Lynch, 2004; Miller and Smart, 2010; Thompson et al., 2010). It has long 
been recognized that, with few exceptions, an Arg at sites corresponding to the 271 position of 
the GlyR α1 subunit is a signature of both the GlyR and GABAAR subunit members (including 
the GlyR α1 subunit) (Figure S1). One of the exceptions is the GlyR β subunit, where an Ala 
exists at this position (Figure 1B). The heteromeric GlyR that incorporates three Ala-carrying β 
subunits together with two α1 subunits exhibits a glycine sensitivity similar to that of the 
homomeric α1 GlyR (Grudzinska et al., 2005; Shan et al., 2001b). On the other hand, replacing 
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the Arg in the α1 GlyR with Ala compromises channel function and mimics the phenotype of the 
α1R271Q/L GlyR (Figure 2A and B) (Lynch et al., 1997).  
 
Supposing that this paradox might be due to a local effect, we replaced the 12-AA segment (262-
273 residues) incorporating the 271 residue in the GlyR α1 subunit with the homologous segment 
from the GlyR β subunit (Figure 1B). The modified subunit was named the GlyR α1Ch subunit 
(Ch is short for chimera) (Figure 1B). Surprisingly, the α1Ch GlyR, which has an Ala at the 271 
position, showed a glycine sensitivity 2600 times higher than the α1R271A GlyR and even an 
order of magnitude higher than the α1WT GlyR (Figure 2B and D, Table 1). Since the α1R271A 
GlyR mimics the phenotype of α1R271Q/L GlyRs, we wondered whether this 12-AA segment 
replacement also restored the function of α1R271Q/L GlyRs. We next introduced either Gln or 
Leu to the 271 position of the α1Ch GlyR. Both constructs demonstrated glycine sensitivities 
20000 (Gln) and 2500 (Leu) times higher than their corresponding substitutions in the α1 GlyR 
(Figure 2B, C and D, Table 1).  We concluded that the 12-AA segment replacement restored the 
function of the α1R271Q/L GlyRs. 
  
As noted above, the α1R271Q/L GlyRs are completely insensitive to activation by the low-
efficacy agonist, taurine (Figure 3A and B) (Rajendra et al., 1995). We thus investigated whether 
the 12-AA replacement also restored the taurine sensitivity of α1R271Q/L GlyRs to WT levels. 
As shown in Figure 3C and D and Table 1, taurine behaved as a full-agonist in activating the 
α1Ch271Q/L/A GlyRs with a sensitivity even higher than in the WT α1 GlyR. We therefore 
concluded that the 12-AA replacement also restored taurine sensitivity of the α1R271Q/L GlyRs. 
 
 9
Replacement of the 12-AA segment incorporating the 271 residue diminishes the residue's 
contribution to channel gating. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
To further characterize the 271 residue in the α1Ch GlyR, we replaced the 271 Ala with Arg, 
which is the residue at the 271 position of the α1WT GlyR. Surprisingly, the α1Ch271R GlyR 
indicated a glycine sensitivity similar to that of the α1Ch271Q/L/A GlyRs (Figure 2C and D, Table 
1), in sharp contrast to the case of the α1 GlyR, where the α1271R(WT) GlyR showed a glycine 
sensitivity 180-400 times higher than the α1R271Q/L/A GlyRs (Figure 2A and B, Table 1). 
Consistently, the α1Ch271R GlyR also demonstrated taurine sensitivity and maximal response 
similar to those of the α1Ch271Q/L/A GlyRs (Figure 3C and D, Table 1). Such insensitivity of the 
α1Ch GlyR to various residue substitutions at the 271 position implies that this residue might have 
a diminished contribution to channel gating in the chimeric receptor.  
 
However, it is also possibly because the energy barrier of the channel gating pathway, which is 
reflected by the glycine EC50s in this case (Colquhoun, 1998), has reached its lowest limit 
(“ceiling effect”) in the α1Ch271Q/L/A GlyRs, as these constructs had very low glycine EC50s, 
around 1 μM (Table 1). In this scenario, the energy barrier (glycine EC50) would not reduce 
further when a more gating-favorable Arg is in place. If that is the case, we argue that the channel 
function should not be enhanced by a potentiator. To test this possibility, we applied the GlyR 
potentiator, propofol (PPF), to the α1Ch271Q GlyR, which exhibited the lowest glycine EC50 
among the Q/L/A substitutions (Table 1). As shown in Figure 4A, PPF enhanced the sub-
saturating glycine induced current by 93 ± 10 % (n = 4). Moreover, PPF left-shifted the glycine 
dose-response curve of the α1Ch271Q GlyR (EC50 < 0.3 μM, n = 4 in the presence of PPF versus 
EC50 = 0.65 ± 0.06 μM, n = 4 in the absence of PPF, Figure 4B and C). Note that it is not possible 
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to quantitate glycine concentrations less than 0.3 μM due to a variable contribution from the 
glycine that inevitably contaminates salt solutions (0.01-0.1 μM). These data imply that the 
energy barrier of the channel gating pathway of the α1Ch271Q GlyR has not reached the lowest 
limit, confirming that the insensitivity of the α1Ch GlyR to various residue substitutions at the 271 
position is due to this residue's diminished contribution to channel gating.  
 
Replacement of the 12-AA segment incorporating the 271 residue alters its local 
microenvironment 
We next sought to determine the underlying mechanism for the different contributions of the 271 
residue to channel gating in the α1 and α1Ch GlyRs. To achieve this, we turned to the voltage-
clamp fluorometry (VCF) technique. VCF detects local conformational changes in the vicinity of 
a residue when the residue is labeled with a fluorescent dye (Gandhi and Isacoff, 2005; Pless and 
Lynch, 2008). Rhodamine fluorescent dyes are usually used, because rhodamine fluorescence 
exhibits an increase in quantum efficiency as the hydrophobicity of its environment is increased. 
Thus, rhodamine fluorescence intensity reports the change of hydrophobicity of its immediate 
microenvironment, which is often caused by local conformational changes. The VCF experiments 
were carried out in Xenopus oocytes as fluorescence detection is not routinely possible in 
HEK293 cell-expressed GlyRs (Pless and Lynch, 2008).   
 
To label the 271 position with a rhodamine fluorescent dye, a cysteine was introduced to this 
position so that the dye can be attached through a disulfide bond (Gandhi and Isacoff, 2005; Pless 
and Lynch, 2008). Interestingly, the α1271C and α1Ch271C GlyRs exhibited glycine EC50 values 
of 4300 ± 200 μM (n = 4) and 2.1 ± 0.4 μM (n = 5), respectively. It is thus evident that the 271C 
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residue behaves in the same manner as the Q/L substitutions, in both the α1Ch and α1 GlyRs. The 
result of the VCF investigation is therefore expected to reflect the behavior of the 271Q/L 
substitutions. 
 
As previously reported (Pless et al., 2007), we confirmed that the rhodamine fluorescent dye 
MTSR, when attached to the 271C residue in the α1 GlyR, exhibited an increase in fluorescence 
intensity (reflected by the upwards step of the fluorescence trace) upon glycine application 
(Figure 5A). This implies that MTSR detected an increase of hydrophobicity in the vicinal 
microenvironment due to a local conformational change during channel gating. Moreover, as the 
fluorescence and current glycine dose-response relationships overlapped, we concluded that the 
local conformational change is coupled with channel gating process. This conclusion is consistent 
with the suggestion that the 271 residue in the α1 GlyR lies within the dominant channel gating 
pathway, as previously proposed (Langosch et al., 1994; Lynch et al., 2001; Lynch et al., 1997; 
Rajendra et al., 1995; Rajendra et al., 1994). 
 
Following the same protocol, the α1Ch271C GlyR was labeled with MTSR and subjected to VCF 
investigation. Surprisingly, no fluorescence change was detected upon glycine application 
(Figure 5A). The 271C residue was possibly not labeled by the MTSR due to structural 
inaccessibility. Alternatively, this residue was labeled, but during channel gating, either no 
conformational change occurred in the vicinity of the 271 residue, or the microenvironment 
hydrophobicity detected by the MTSR fluorophore was not altered even though a local 
conformational change took place. Nevertheless, such different behaviors of the 271 residue 
between the α1 and α1Ch GlyRs suggest that either the static microenvironment or the dynamic 
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microenvironment change during channel gating, or both, in the vicinity of the 271 residue in the 
α1Ch GlyR are altered by the 12-AA segment replacement from those in the α1 GlyR. 
  
Considering that rhodamine fluorophores are structurally different and may thus respond 
differently to a given conformational change when attached to the α1271C GlyR (Pless et al., 
2007), we next investigated the response of another rhodamine fluorescent dye TMRM in the 
α1271C and α1Ch271C GlyRs. In the TMRM-labeled α1271C GlyR, the fluorescence intensity was 
increased upon glycine application (reflected by the upwards step of the fluorescence trace, 
Figure 5B). In contrast, in the TMRM-labeled α1Ch271C GlyR, the fluorescence intensity was 
decreased upon glycine application (reflected by the downwards step of the fluorescence trace, 
Figure 5D). Such different direction of fluorescence intensity change provides a more direct 
indication that either the static microenvironment or the dynamic microenvironment change, or 
both, during channel gating, in the vicinity of the 271 residue in the α1ChGlyR, are distinct from 
those in the α1 GlyR. 
 
More interestingly, the dose-response curve of fluorescence was right-shifted from that of current 
in the α1Ch271C GlyR when TMRM was used (fluorescence EC50 = 36 ± 8 μM, n = 4 versus 
current EC50 = 2.0 ± 0.2 μM, n = 5, p < 0.01, Figure 5E). This is in contrast with the α1271C 
GlyR, where the dose-response curves of fluorescence and current overlapped (fluorescence EC50 
= 770 ± 150 μM, n = 5 versus current EC50 = 960 ± 120 μM, n = 5, p > 0.05, Figure 5C), 
consistent with what was observed when MTSR was used (Pless et al., 2007). These data suggest 
that the conformational change in the vicinity of the 271 residue in the α1Ch271C GlyR, unlike in 
the α1271C GlyR, is uncoupled from the channel gating process. We hence propose that, in the 
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α1Ch GlyR, the 271 residue is not essential for channel gating and might not reside within the 
dominant channel gating pathway. Such a proposal is also supported by the fact that the α1Ch 
GlyR channel function is not sensitive to various residue substitutions at the 271 position, as 
described above. 
 
Discussion 
The function of α1R271Q/L GlyRs is restored by shifting the affected residue out of the 
dominant channel gating pathway. 
Here we report that replacement of a 12-AA segment incorporating the 271 residue of the GlyR 
α1 subunit with the homologous segment of the GlyR β subunit restores channel function of the 
hereditary hyperekplexia-causing α1R271Q/L GlyRs. More interestingly, through residue 
substitution and VCF investigation, we concluded that this rescue effect is achieved by adjusting 
the local microenvironment and in consequence diminishing the 271 residue's contribution to 
channel gating. It has been proposed that multiple allosteric signaling pathways exist in proteins, 
and which pathways dominate is determined by protein topologies, specific binding events, 
covalent modifications and cellular conditions (del Sol et al., 2009). Residue replacement, which 
potentially changes the protein topology (Sinha and Nussinov, 2001), can shift the dominant 
signaling pathway from one pathway to another. In our experiment, the 271 residue lies within 
the dominant channel gating pathway in the α1 GlyR. However, the 12-AA segment replacement 
induces a local conformational change and, in consequence, shifts the dominant channel gating 
pathway to an alternative one, where the 271 residue does not reside (Figure 6A). The hypothesis 
that the 271 residue does not reside within the dominant channel gating pathway is reminiscent of 
ivermectin induced GlyR channel activation. Ivermectin is a GlyR agonist, which binds to the 
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GlyR and gates the channel opening in a manner distinct from the physiological agonist glycine 
(Hibbs and Gouaux, 2011; Pless et al., 2007; Shan et al., 2001a). For example, the α1 GlyR 
function activated by ivermectin is almost conserved when the R271Q mutation is introduced 
(Shan et al., 2001a). Moreover, the MTSR-labeled α1271C GlyR does not show any fluorescence 
change upon ivermectin application (Pless et al., 2007). Both observations imply that the 271 
residue does not reside within the ivermectin mediated channel gating pathway.  
 
Implications for a residue-specific drug design strategy 
Many pathophysiological conditions are caused by residues being either missense mutated or 
abnormally covalently modified (for example, by phosphorylation). The relevant treatment 
strategy is usually symptomatic. For example, to treat GlyR mutation-caused hereditary 
hyperekplexia, benzodiazepines, such as clonazepam, are used (Thomas et al., 2010; Zhou et al., 
2002). The benzodiazepines, which are GABAAR potentiators, can counter the over-excitation 
symptoms due to the compromised GlyR function. However, such an “off-target” treatment 
strategy is the source of a wide range of side effects. 
 
A more specific treatment strategy is to directly target the affected protein. A drug is usually 
designed either to enhance (in loss-of-function) or to inhibit (in gain-of-function) the function of 
the affected protein. However, these effects are usually global rather than mutation- or 
modification-specific, as the drug affects the WT or naïve protein as well as the mutant or 
modified protein (Joerger and Fersht, 2007; Wang et al., 2003). This will lead to a lack of 
specificity as proteins usually have multiple subtypes (e.g α1, α2 and α3 GlyRs) of different 
genomic origins, which share a high degree of homology and, in consequence, similar structure 
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and function relationships. Any drug acting on one subtype (e.g. the mutant protein, GlyR 
α1R271Q/L) has a very high chance of affecting other subtypes (e.g. other WT subtypes of the 
mutant protein such as GlyR α2 and α3) as well. As protein subtypes are usually distributed in 
various tissues and thus have different physiological or pathological roles from each other, a drug 
that is supposed to only act on the specific target subtype in the ideal state but affects multiple 
other subtypes in reality, will cause undesirable side effects. Another consideration is that 
abnormal residue covalent modification of a given protein under a certain pathological condition 
usually only occurs in a localized region of the human body. A drug that affects the naïve as well 
as the modified proteins may correct the modifications in the localized region, but would also 
interfere with processes in other regions where the target protein expresses but without any 
modification. This is another source of undesirable side-effects.  
 
One way to circumvent this “global effect” is to design a residue (mutant or modified)-specific 
drug. This ideal drug should affect the mutant or modified protein but not the WT or naïve 
protein. Despite many attempts, this goal has been successfully achieved in only a few cases. One 
successful case is the mutant p53-targeting drug, PRIMA-1.  PRIMA-1 affects the function of 
mutant p53 but not the WT p53 (Bykov et al., 2002a; Bykov et al., 2002b), through a mechanism 
of modifying thiol groups within the protein (Lambert et al., 2009). However, such a mechanism 
apparently cannot become a universal strategy for mutant or modified protein-specific drug 
design. 
 
We proposed in this article that the affected residue could be shifted out of the dominant 
allosteric signaling pathway by the local conformational change induced by residue substitutions. 
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Since binding of a small molecule, like residue substitutions, can also induce conformational 
change and redistribute the dominant signaling pathway (del Sol et al., 2009; Kar et al., 2010; 
Kumar et al., 2000; Todd and Freire, 1999), our proposal could form the basis for a universal 
mutant or modified residue-specific drug design strategy: an allosteric drug (Kar et al., 2010) can 
be designed to alter the microenvironment in the vicinity of the affected residue and to activate an 
alternative allosteric signaling pathway that excludes the affected residue (Figure 6A). This drug 
action can be realized to have a neutral effect on the WT or naïve protein through activating the 
alternative allosteric signaling pathway with a strength equivalent to the original one (Figure 6A). 
However, the drug should restore the function of the mutant or modified proteins to the WT level, 
since the affected residue is no longer within the dominant allosteric signaling pathway and hence 
does not affect the protein function (Figure 6A). This missense mutation- or covalent 
modification-specific drug design strategy would help tackle one of the most serious problems 
existing among the drugs clinically used today: lack of specificity.  
 
Possible drug design strategy for the GlyR R271Q/L hereditary hyperekplexia 
The 12-AA segment that restores the function of the α1R271Q/L GlyR is located along the 
extracellular half of the M2 segment and the M2-M3 domain (Figure 1A and 6B). Both domains, 
together with the extracellular halves of the M1 and M3 segments, form a cavity, which contains 
the binding site of many clinically related drugs or substances including alcohol (Mihic et al., 
1997) , neurosteroids (Hosie et al., 2006), general anesthetics (Nury et al., 2011) and ivermectin 
(Collins and Millar, 2010; Hibbs and Gouaux, 2011; Lynagh and Lynch, 2010) and therefore can 
be used as the potential docking site for drugs that specifically correct the GlyR R271Q/L 
mutations. Interestingly, the general anesthetic, PPF, which binds into this cavity and potentiates 
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the GlyR function, restores the WT phenotype of the hyperekplexic GlyR R271Q transgenic mice 
(O'Shea et al., 2004), although a wide range of side effects would be expected, since PPF also 
potentiates the GABAAR and inhibits the nicotinic acetylcholine receptor (nAChR) (Franks, 
2008). Nevertheless, PPF could possibly serve as the seeding backbone for designing a drug 
specifically correcting the GlyR R271Q/L mutations. The final ideal GlyR R271Q/L mutation 
corrector, by exploiting the novel drug design strategy proposed in the article, could be achieved 
to affect the function of the α1R271Q/L GlyR but not any other protein including the α1WT, α2 α3 
GlyRs and closely related GABAAR and nAChR.  
It should be noted though that this mutation corrector is only effective in treating hereditary 
hyperekplexia caused by α1R271Q/L mutations, but not by any mutation arising from other sites 
of the GlyR α1 subunit, from the GlyR β subunit or from the SLC6A5 glycine transporter. 
Considering that the absolute number of patients diagnosed with hyperekplexia caused by 
α1R271Q/L mutations is low, it might not be commercially feasible to develop a specific 
α1R271Q/L mutation corrector. Instead, the target-specific drug design strategy we propose here 
provides a general principle for developing drugs that correct mutations or abnormal residue-
modifications in proteins. 
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 Table 1, Properties of glycine- and taurine- induced currents of GlyRs. 
GlyR glycine  taurine 
EC50 (μM) n  EC50 (μM) Imax,tau/Imax,gly (%) n 
α1       
271R(WT) 33 ± 2 4  261 ± 32 99 ± 1 3 
271A 5700 ± 1600 4  N.D. 0 3 
271Q 13200 ± 2000 4  N.D. 0 3 
271L 8000 ± 490 3  N.D. 0 3 
       
α1Ch       
271R 0.87 ± 0.19 4  3.7 ± 0.3 92 ± 5 4 
271A(WT) 2.2 ± 0.2 4  8.7 ± 0.9 99 ± 1 4 
271Q 0.65 ± 0.06 4  7.3 ± 0.7 95 ± 2 4 
271L 3.4 ± 1.1 4  16 ± 3 100 ± 0 4 
3 
4 
N.D., not determined because taurine exhibited no agonist efficacy 
 25
Figure legends 1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
Figure 1: Location of the 271 residue on the GlyR α1 subunit. (A) In structural models of the 
pentameric GlyR (top view, left panel) and single α1 subunit (side-view, right panel) (Chung et 
al., 2010), the 271 residue (red) is physically located between the agonist binding site and the 
channel gate. The 12-amino-acid segment incorporating the 271 residue is highlighted in blue in 
the model of single α1 subunit. (B) Sequences of the M2 and M2-M3 domains of the GlyR α1, β, 
and α1Ch subunits are shown. The 271 residues are underlined. 
 
Figure 2: Effects of various substitutions of the 271 residue on the glycine sensitivity of the 
α1 and α1Ch GlyRs. Example traces of currents induced by increasing glycine concentrations in 
the indicated constructs of the α1 and α1Ch GlyRs are shown in (A) and (C), respectively. 
Averaged normalized glycine dose–response curves for various substitutions of the 271 residue 
of the α1 and α1Ch GlyRs are shown in (B) and (D), respectively (n = 3 or 4).  
 
Figure 3: Effects of various substitutions of the 271 residue on the taurine sensitivity of the 
α1 and α1Ch GlyRs. Example traces of currents induced by increasing taurine concentrations in 
the indicated constructs of the α1 and α1Ch GlyRs are shown in (A) and (C), respectively. 
Averaged normalized taurine dose–response curves for various substitutions of the 271 residue of 
the α1 and α1Ch GlyRs are shown in (B) and (D), respectively (n = 3 or 4).  
 
Figure 4: Propofol potentiation of α1Ch271Q GlyR function. (A) Example of propofol 
potentiating sub-saturating glycine-induced α1Ch271Q GlyR currents. (B) Example traces of 
α1Ch271Q GlyR currents induced by increasing glycine concentrations in the absence and 
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presence of propofol. (C) Averaged normalized glycine dose–response curves of the α1Ch271Q 
GlyR in the absence and presence of propofol (n = 4).  
 
Figure 5: VCF of the α1 and α1Ch GlyRs. Example current (I) and fluorescence (F) traces of the 
α1271C and α1Ch271C GlyRs labeled with MTSR or TMRM are shown in (A), (B) and (D). 
Averaged normalized glycine dose-response curves of current (I) and fluorescence (F) of the 
α1271C and α1Ch271C GlyRs labeled with TMRM are shown in (C) and (E), respectively (n = 4 
or 5).  
 
Figure 6: Model of the residue-specific drug design strategy. (A) In a protein with a certain 
residue, either mutant or modified (red circle), the protein function is compromised because the 
affected residue blocks the dominant allosteric signaling pathway (green strip).  The protein 
function can be restored by activating an alternative allosteric signaling pathway that does not 
include the affected residue. This restoration can be achieved through adjusting the local 
microenvironment, either internally, by substituting the amino acids in the vicinity of the affected 
residue (blue line), or externally, by applying a drug (blue triangle) that has an equivalent effect 
as the vicinal amino acid substitution. If the newly activated alternative allosteric signaling 
pathway has equivalent strength as the original one in the WT or naïve protein, neither the vicinal 
amino acid substitution nor external drug application apparently affects the WT or naïve protein 
function. (B) When designing a drug (blue triangle) that specifically corrects the GlyR 271Q/L 
mutations (red residue), a possible docking site for this drug is the cavity formed by the 
extracellular halves of the M1, M2 and M3 segments and the M2-M3 domain, which is the 
binding site of many clinically related drugs and substances. The location of the 271 residue and 
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the potential drug molecule are indicated in the structural models of the pentameric GlyR (top 
view, top panel) and single α1 subunit (side view, bottom panel) (Chung et al., 2010). 
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